Management of attention-deficit/hyperactivity disorder: The importance of psychosocial and medication treatments

Journal of Paediatrics and Child Health

Volumn 48, Issue 2, 2012, Pages

  Vance, Alasdair ^a   Winther, Jo ^a   Rennie, Kelly ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ADHD; assessment; medication treatment; psychosocial treatment

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; COMORBIDITY; HUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK FACTOR;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; DISEASE MANAGEMENT; HUMANS; PSYCHOLOGY; RISK FACTORS;

EID: 80052983382     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2010.01941.x     Document Type: Review

References (39)

1. Vance A,. A current treatment approach for ADHD. Aust. Prescriber 2008; 31: 129-32.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
3. Simonoff E, Pickles A, Meyer JM, et al,. The Virginia Twin Study of Adolescent Behaviour Disorder: influences of age, sex and impairment on rates of disorder. Arch. Gen. Psychiatry 1997; 54: 785-9.
4. Rucklidge JJ,. Gender differences in ADHD. Psychiatr. Clin. North Am. 2010; 33: 357-73.
5. Crews D,. Epigenetics and its implications for behavioral neuroendocrinology. Front. Neuroendocrinol. 2008; 29: 344-57.
6. DasBanerjee T, Middleton FA, Sagvolden T, Faraone SV,. A comparison of molecular alterations in environmental and genetic rat models of ADHD: a pilot study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008; 147B: 1554-63.
7. Bellgrove MA, Hawi Z, Mullins C, Robertson IH, Gill M,. COMT polymorphism affects prefrontal cognition in children and adolescents with ADHD. Exp. Brain Res. 2005; 163: 352-60. (Pubitemid 41175258)
8. Ficks CA, Walderman I,. Gene-environment interactions in ADHD. Curr. Psychiatry Rep. 2009; 11: 382-92.
9. Levy F,. Dopamine vs. noradrenalone: inverted-U effects and ADHD theories. Aust. N. Z. J. Psychiatry 2009; 43: 101-8.
10. Castellanos FX, Lee PP, Sharp W,. Developmental trajectories of brain volume: abnormalities in children and adolescents with ADHD. JAMA 2002; 288: 1740-8.
11. Cubillo A, Halari R, Ecker C, Taylor E, Rubia K,. Reduced activation and inter-regional functional connectivity of fronto-striatal networks in adults with childhood Attention-Deficit Hyperactivity Disorder (ADHD) and persisting symptoms during tasks of motor inhibition and cognitive switching. J. Psychiatr. Res. 2010; 44: 629-39.
12. Awh E, Jonides J,. Overlapping mechanisms of attention and spatial working memory. Trends Cogn. Sci. 2001; 5: 119-26. (Pubitemid 32178172)
13. Taylor E,. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur. Child Adolesc. Psychiatry 2004; 13 (Suppl. 1): 1/7-1/30.
14. Taylor E, Rogers JW,. Practitioner review: early adversity and developmental disorders. J. Child Psychol. Psychiatry 2005; 46: 451-67. (Pubitemid 40614090)
15. Froehlich T, Lanphear BP, Auinger P, et al,. Association of tobacco and lead exposures with ADHD. Pediatrics 2009; 124: 1054-63.
16. Pliszka S,; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 2007; 46: 894-921.
17. RACP. Australian Guidelines on ADHD. Melbourne, Australia: RACP, 2009.
18. Bloch MH, Panza KE, Leckman JF,. Meta-analysis: treatment of ADHD in children and adolescents with comorbid tic disorders. J. Am. Acad. Child Adolesc. Psychiatry 2009; 48: 884-93.
19. Maughan B, Rowe R, Messer J,. Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology. J. Child Psychol. Psychiatry 2004; 45: 609-21. (Pubitemid 38380137)
20. National Institute for Health and Clinical Excellence (NICE). Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guideline 72. London: The British Psychological Society and The Royal College of Psychiatrists, 2009.
21. Young S, Amarasinghe JM,. Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach. J. Child Psychol. Psychiatry 2010; 51: 116-33.
22. Evidence Based Service Committee 2007 Biennial Report. Effective Psychosocial Interventions for Youth with Behavioural and Emotional Needs. Honolulu, HI: Hawaii Department of Health, Child and Adolescent Mental Health Division, 2007.
23. Garland AF, Hawley KM, Brookman-Frazee L, Hurlburt MS,. Identifying common elements of evidence-based psychosocial treatments for children's disruptive behaviour problems. J. Am. Acad. Child Adolesc. Psychiatry 2008; 47: 505-14. (Pubitemid 351591599)
24. Pelham WE, Wheeler T, Chronis A,. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J. Child Psychol. Psychiatry 1998; 27: 190-205.
25. DuPaul GJ, Evans SW,. School-based interventions for attention deficit hyperactivity disorder. Adolesc. Med. State Art Rev. 2008; 19: 300-12.
26. Barkley RA, Edwards G, Laneri M, Fletcher K, Metevia L,. The efficacy of problem-solving communication training alone, behaviour management training alone, and their combination for parent-adolescent conflict in teenagers with ADHD and ODD. J. Consult. Clin. Psychol. 2001; 69: 926-41. (Pubitemid 33140494)
27. Daly BP, Creed T, Xanthopoulos M, Brown RT,. Psychosocial treatments for children with ADHD. Neuropsychol. Rev. 2007; 17: 78-89.
28. Pelham WE, Fabiano GA,. Evidence-based psychosocial treatments for ADHD. J. Clin. Child Adolesc. Psychol. 2008; 37: 184-214.
29. Froehlich TE, McGough JJ, Stein MA,. Progress and promise of ADHD pharmacogenomics. CNS Drugs 2010; 24: 99-117.
30. Faraone SV, Buitelaar J,. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur. Child Adolesc. Psychiatry 2010; 19: 353-64.
31. Murray DW, Arnold LE, Swanson J, Jensen P, Hechtman L, Strauss T,. A clinical review of outcomes of the MTA study. Curr. Psychiatr. Rep. 2008; 10: 424-31.
32. MTA Cooperative Group. The MTA at 8 years: prospective follow up of children treated for combined type ADHD in a multisite study. J. Am. Acad. Child Adolesc. Psychiatry 2009; 48: 484-500.
33. Buitelaar J, Medori R,. Treating ADHD beyond symptom control alone in children and adolescents: a review of the potential benefits of long acting stimulants. Eur. Child Adolesc. Psychiatry 2010; 19: 325-40.
34. Garnock-Jones KP, Keating GM,. Spotlight on atomoxetine in ADHD in children and adolescents. CNS Drugs 2010; 24: 85-8.
35. May DE, Kratochvil CJ,. ADHD: recent advances in paediatric pharmacotherapy. Drugs 2010; 70: 15-40.
36. Arnsten AF,. Toward a new understanding of ADHD pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23 (Suppl. 1): 33-41.
37. Jensen PS, Hinshaw SP, Kraemer HC, et al,. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J. Am. Acad. Child Adolesc. Psychiatry 2001; 40: 147-58. (Pubitemid 32111018)
38. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ,. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 2002; 6 (Suppl. 1): S31-43.
39. Volkow ND, Fowler JS, Wang G, Telang F, Benveniste H, Swanson JM,. Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task. PLoS ONE 2008; 3: e2017.